|Bid||4.4700 x 3200|
|Ask||4.5200 x 1200|
|Day's Range||4.3600 - 4.5800|
|52 Week Range||2.6000 - 12.3390|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
CULVER CITY, Calif., July 28, 2022--The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease. ImmunityBio, a leading clinical-stage immunotherapy company, filed the BLA based on positive results from a series of studies of the investigational treatment, including the o
A new generation of vaccines is needed to continue fighting COVID-19, according to experts at the White House Tuesday.
The Los Angeles-based company is far different from Athenex, developing different kinds of cancer drugs and building its own business model around those plans, but it also has some notable similarities.